SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice-Reference-Cited by-同舟云学术

SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice

Published:2018-07-23 Issue:5 Volume:9 Page:1757-1773
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Wilding John,Fernando Kevin,Milne Nicola,Evans Marc,Ali Amar,Bain Steve,Hicks Debbie,James June,Newland-Jones Philip,Patel Dipesh,Viljoen Adie

Funder

Napp Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13300-018-0471-8.pdf

Reference48 articles.

1. Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther. 2014;5(2):355–66.

2. Napp Pharmaceuticals Limited. Canagliflozin: summary of product characteristics. 2017. https://www.medicines.org.uk/emc/product/8855 . Accessed April 2018.

3. AstraZeneca UK Limited. Dapagliflozin: summary of product characteristics. 2017. https://www.medicines.org.uk/emc/product/7607 . Accessed April 2018.

4. Boehringer Ingelheim Limited. Empagliflozin: summary of product characteristics. 2018. https://www.medicines.org.uk/emc/product/5441 . Accessed April 2018.

5. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. 2017. https://www.nice.org.uk/guidance/ng28 . Accessed April 2018.

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SGLT2 inhibition improves PI3Kα inhibitor–induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials;Breast Cancer Research and Treatment;2024-08-23

2. SGLT2 inhibitor Dapagliflozin alleviates cardiac dysfunction and fibrosis after myocardial infarction by activating PXR and promoting angiogenesis;Biomedicine & Pharmacotherapy;2024-08

3. Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk;Diabetes, Obesity and Metabolism;2024-06-10

4. Medication Use in Older Adults With Type 2 Diabetes;ADCES in Practice;2024-05-31

5. SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review;Diabetes Therapy;2024-04-05